Thus, CRAd-synNotch is expected to not only exhibit antitumor effects through the synNotch gene but also enable tumor dissolution due to the activity of the COX-2 promotor gene, and these effects are anticipated to occur regardless of the malignancy level of the cancer. Here, PTGS2 is linked to cancer.